colchicine


( Last Updated : November 18, 2021)
Generic Name:
colchicine
Project Status:
Active
Therapeutic Area:
Atherothrombotic events in coronary artery disease
Manufacturer:
Pendopharm, a division of Pharmascience Inc.
Brand Name:
Myinfla
Project Line:
Reimbursement Review
Project Number:
SR0691-000
NOC Status at Filing:
Pre NOC

Details


Manufacturer Requested Reimbursement Criteria1:
For reduction of atherothrombotic events in patients with existing coronary artery disease who had a myocardial infarction.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Reduction of atherothrombotic events in adult patients with existing coronary artery disease, in addition to standard therapies, including LDL-C lowering and antithrombotic drug treatment.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Submit Feedback

Key Milestones

Call for patient/clinician input open 29-Apr-21
Call for patient/clinician input closed 18-Jun-21
Clarification:

- No patient input submission received

Submission received 28-May-21
Submission accepted 11-Jun-21
Review initiated 14-Jun-21
Draft CADTH review report(s) provided to sponsor for comment 27-Aug-21
Deadline for sponsors comments 08-Sep-21
CADTH responses on draft review report(s) provided to sponsor 15-Oct-21
Expert committee meeting (initial) 27-Oct-21
Draft recommendation issued to sponsor 10-Nov-21
Draft recommendation posted for stakeholder feedback 18-Nov-21
End of feedback period 02-Dec-21